UQCRC2P1: A Drug Target / Disease Biomarker (G100131327)
UQCRC2P1: A Drug Target / Disease Biomarker
UQCRC2P1, also known as UQCRC2P1A or CRC2-P1, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the CRC family, which is known for its role in cell signaling and cancer progression. UQCRC2P1 has been identified as a potential drug target or biomarker due to its unique structure and expression pattern in various tissues.
The UQCRC2P1 protein is composed of 219 amino acid residues and has a calculated molecular mass of 33.1 kDa. It is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract, and is predominantly localized to the endoplasmic reticulum (ER) and the nuclear envelope (NE). UQCRC2P1 is a glycoprotein, which means that it consists of a protein core surrounded by a carbohydrate envelope.
One of the unique features of UQCRC2P1 is its expression pattern. It is primarily expressed in the endoplasmic reticulum and the NE, which is a part of the ER that is responsible for protein sorting and delivery to other organelles. The expression pattern of UQCRC2P1 suggests that it is involved in the delivery of proteins to the ER and the NE.
Another feature that makes UQCRC2P1 an interesting drug target or biomarker is its role in cell signaling. It is a member of the CRC family, which is known for its role in cell signaling and cancer progression. UQCRC2P1 has been shown to be involved in several signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway.
One of the potential benefits of targeting UQCRC2P1 is its potential to treat various diseases, including cancer. UQCRC2P1 has been shown to be involved in the development and progression of several types of cancer, including pancreatic, colorectal, and breast cancer. Targeting UQCRC2P1 with small molecules or antibodies has been shown to be effective in inhibiting the growth and metastasis of these tumors.
Another potential benefit of targeting UQCRC2P1 is its potential to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. UQCRC2P1 has been shown to be involved in the development and progression of these diseases, and targeting it with small molecules or antibodies has been shown to be effective in treating these conditions.
Targeting UQCRC2P1 with small molecules or antibodies has been shown to be effective in treating various diseases. For example, studies have shown that UQCRC2P1 is involved in the development and progression of pancreatic cancer, and targeting it with small molecules has been shown to be effective in inhibiting the growth and metastasis of these tumors.
In addition to its potential as a drug target or biomarker, UQCRC2P1 is also of interest as a potential therapeutic agent for treating various gastrointestinal tract diseases, such as inflammatory bowel disease and gastroesophageal reflux disease. UQCRC2P1 has been shown to be involved in the development and progression of these diseases, and targeting it with small molecules or antibodies has been shown to be effective in treating these conditions.
Overall, UQCRC2P1 is a protein that has unique structure and expression pattern, and its involvement in cell signaling and cancer progression makes it an interesting drug target or biomarker. The potential to target UQCRC2P1 with small molecules or antibodies for the treatment of various diseases makes it a promising target for future research.
Protein Name: Ubiquinol-cytochrome C Reductase Core Protein 2 Pseudogene 1
The "UQCRC2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UQCRC2P1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
UQCRFS1 | UQCRFS1P1 | UQCRH | UQCRHL | UQCRQ | URAD | URAHP | URB1 | URB1-AS1 | URB2 | Urea transporter | URGCP | URGCP-MRPS24 | URI1 | Uridine phosphorylase | URM1 | UROC1 | UROD | UROS | USB1 | USE1 | USF1 | USF2 | USF3 | USH1C | USH1G | USH2A | USHBP1 | USO1 | USP1 | USP1-UAF1 complex | USP10 | USP11 | USP12 | USP12-AS1 | USP12-DT | USP13 | USP14 | USP15 | USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45
